Abstract
The transcription of antioxidant response element (ARE)-containing cytoprotective genes has been proposed as a means to combat oxidative stress-related disorders, such as cancer and Parkinsons disease. Transactivation of the ARE requires the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). Cellular levels of Nrf2 protein are regulated by the Kelch-like ECH-associated protein 1 (Keap1), a substrate adaptor protein for the ubiquitin ligase machinery and subsequent proteasomal degradation. Recently, detailed studies have elucidated the structure and interactions of the Keap1-containing ubiquitin ligase complex. Here, we propose that small molecule modulation of Keap1 protein:protein interactions may permit Nrf2s nuclear accumulation and the transcription of AREdependent genes to enhance cellular resistance to oxidative insult.
Keywords: Keap1, Nrf2, Cul3, antioxidant, oxidative stress, antioxidant response element
Current Topics in Medicinal Chemistry
Title: Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Volume: 7 Issue: 10
Author(s): Jonathan T. Kern, Mark Hannink and J. Fred Hess
Affiliation:
Keywords: Keap1, Nrf2, Cul3, antioxidant, oxidative stress, antioxidant response element
Abstract: The transcription of antioxidant response element (ARE)-containing cytoprotective genes has been proposed as a means to combat oxidative stress-related disorders, such as cancer and Parkinsons disease. Transactivation of the ARE requires the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). Cellular levels of Nrf2 protein are regulated by the Kelch-like ECH-associated protein 1 (Keap1), a substrate adaptor protein for the ubiquitin ligase machinery and subsequent proteasomal degradation. Recently, detailed studies have elucidated the structure and interactions of the Keap1-containing ubiquitin ligase complex. Here, we propose that small molecule modulation of Keap1 protein:protein interactions may permit Nrf2s nuclear accumulation and the transcription of AREdependent genes to enhance cellular resistance to oxidative insult.
Export Options
About this article
Cite this article as:
Kern T. Jonathan, Hannink Mark and Fred Hess J., Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy, Current Topics in Medicinal Chemistry 2007; 7 (10) . https://dx.doi.org/10.2174/156802607780906825
DOI https://dx.doi.org/10.2174/156802607780906825 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Implications of CYP2D6 Genetic Polymorphism During Treatment with Antipsychotic Drugs
Current Drug Targets Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Nanotechnology Driven Approaches for the Management of Parkinson’s Disease: Current Status and Future Perspectives
Current Drug Metabolism Antipsychotic Medication: The Potential Role of 5-HT1A Receptor Agonism
Current Pharmaceutical Design Serum Vitamin E (α-Tocopherol) Estimation: A Potential Biomarker of Antioxidant Status Evaluation on Heavy Metal Toxicities
Recent Patents on Biomarkers N-3 (Omega-3) Fatty Acids: Effects on Brain Dopamine Systems and Potential Role in the Etiology and Treatment of Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs
Current Pharmaceutical Design Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine The GABA Shunt: An Attractive and Potential Therapeutic Target in the Treatment of Epileptic Disorders
Current Drug Metabolism COMMENTARY: Magnetic Resonance Techniques Applied to Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia
CNS & Neurological Disorders - Drug Targets Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer’s Disease Therapy: Advances in Chemical and Biological Research
Current Medicinal Chemistry Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Serotonin Receptor Binding Characteristics of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook
Current Medicinal Chemistry Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacokinetics, Disposition, and Metabolism of [14C]-Nebicapone in Humans
Drug Metabolism Letters Oxidative Stress in the Early Stage of Psychosis
Current Topics in Medicinal Chemistry Genotyping as a Tool to Predict Adverse Drug Reactions
Current Topics in Medicinal Chemistry